Produced by The National Diabetes Guidelines Group.
The NZSSD working group, with support of the Ministry of Health, develops national up-to-date and evidence-based guidance for the management of type 2 diabetes in adults that will continue to be updated as evidence and practice changes.
In the new 2023 algorithm, lifestyle management and metformin remain the first-line interventions and the recent shift towards reducing CV, renal risk and obesity are emphasised, in addition to improving glycaemic control.
Specific changes to the updated guidance include the following.
Kathy joined Pinnacle earlier this month as clinical diabetes specialist for Waikato, replacing the role previously held by Anne Waterman.
Read moreFrom 1 December 2025, Pharmac will remove Special Authority renewal requirements for several treatments, including insulin pump consumables, continuous glucose monitors, LAMA/LABA inhalers, epoetin alfa, budesonide capsules, and febuxostat.
Read moreFunding for patients who require a follow-up appointment following HbA1c retest by Awanui Labs.
This funding ends on 28 February 2026
A guide for clinical management of type 2 diabetes, to support nurses at all levels to develop their knowledge and clinical reasoning in diabetes care.